Development of the T-ALLiPSC-based therapeutic cancer vaccines for T-cell acute lymphoblastic leukemia

Med Oncol. 2022 Sep 29;39(12):200. doi: 10.1007/s12032-022-01809-6.

Abstract

The T-cell acute lymphoblastic leukemia (T-ALL) is a kind of hematological malignancy in children. Despite the significant improvement in the cure rate of T-ALL upon treatment with chemotherapy regimens, steroids, and allotransplantation there are relapses. This study focuses on the tumor-specific therapeutic vaccines derived from the induced pluripotent stem cells (iPSC) to address the issue of T-ALL recurrence. Patient-derived tumor cells and healthy donor cells were reprogrammed into the iPSCs and the RNA-seq data of the T-ALL-iPSCs and H-iPSCs were analyzed. In vitro, the whole-cell lysate antigens of iPSCs were prepared to induce the dendritic cells (DC) maturation, which in turn stimulated the tumor-specific T cells to kill the T-ALL tumor cells (Jurkat, CCRF-CEM, MOLT-4). The cytotoxic T lymphocyte stimulated by the DC-loaded T-ALL-iPSC-derived antigens showed specific cytotoxicity against the T-ALL cells in vitro. In conclusion, the T-ALL-iPSC-based therapeutic cancer vaccine can elicit a specific anti-tumor effect on T-ALL.

Keywords: Cancer vaccine; Cytotherapy; Induced pluripotent stem cells; T-ALL.

MeSH terms

  • Cancer Vaccines* / therapeutic use
  • Child
  • Dendritic Cells
  • Humans
  • Induced Pluripotent Stem Cells*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • T-Lymphocytes, Cytotoxic

Substances

  • Cancer Vaccines